TABLE 1.
Effect of ATGL and HSL inhibitors on NEFA release in 3T3-L1 and BA cells 3 hours following incubation with isoproterenol or ABHD5 ligands.
All values are expressed as a percentage of time-matched treatments without inhibitors.
| Compound | Atglistatin (10 μM) | BAY (5 μM) | Atglistatin (10 μM) + BAY (5 μM) | |||
|---|---|---|---|---|---|---|
| % NEFA Inhibition (3T3-L1) | % NEFA Inhibition (BA) | % NEFA Inhibition (3T3-L1) | % NEFA Inhibition (BA) | % NEFA Inhibition (3T3-L1) | % NEFA Inhibition (BA) | |
| DMSO | 72 ± 1.7b | 51 ± 8.3a | 67 ± 2.9 | 19 ± 11 | 90 ± 2.1a | 58 ± 6.2a |
| ISO | 54 ± 4.9a | 90 ± 2.1b | 80 ± 1.6 | 23 ± 3.9 | 97 ± 0.37c | 96 ± 0.92c |
| SR-3420 | 75 ± 3.7b | 87 ± 2.1b | 79 ± 1.7 | 18 ± 2.2 | 96 ± 0.22b | 92 ± 1.4b |
| SR-4995 | 70 ± 7.1b | 80 ± 5.5b | 73 ± 6.6 | 9.2 ± 5.2 | 95 ± 1.1b | 80 ± 8.0b |
| SR-4559 | 77 ± 2.0b | 83 ± 2.4b | 71 ± 0.59 | 0.92 ± 5.6 | 94 ± 1.2b | 83 ± 4.2b |
a,b,c
Letters denote significant differences in NEFA levels among treatments within each cell line and inhibitor class (P < 0.05).